Navigation Links
M3 Global Research Expands Qualitative Research Department- Next Important Step in M3 Group Growth Strategy
Date:12/5/2013

Washington, DC (PRWEB) December 05, 2013

M3 Global Research, (http://research.m3.com), a market leader with the world’s largest verified healthcare professional panel, today announced two important leadership changes to help accelerate the company’s global growth: the appointment of Alan Mavretish as Vice President of Market Research and the promotion of Brooke Allen-Watson to US Qualitative Manager.

Mr. Mavretish previously worked at online Qualitative platform pioneer iTracks and Baxter Healthcare, and has nearly 20 years of qualitative research experience. He earned a degree in Business Administration from Duquesne University and will be based in Pennsylvania. Ms. Allen-Watson has 7 years of qualitative experience and previously worked for Focus Pointe Global and FocusForward.

Last week M3 announced the doubling of its digital US physician reach through an exclusive agreement with PDR, (http://mdlinx.pdr.net), one of the most trusted names by physicians. M3 now reaches over 2.5 million physicians worldwide digitally and has a healthcare professional reach that exceeds 4 million when including nurses, dentists, physician assistants, lab managers, payers, and pharmacists.

“M3 has quickly grown to be a market leader in Qualitative Healthcare Research around the world adding capabilities in the US and Japan this year which complement our market leading EU capabilities which feature a London based call center and studios in Hammersmith,” said Bill Friedrich Director of Market Research Services.

M3 Global Research is the only healthcare panel in the world ISO certified to the market research standard ISO26362. “2013 has been a pivotal year for M3 Global Research to expand global panel coverage and attract top notch talent to keep our expanding client base serviced with the highest quality healthcare data collection service,” said Roni DasGupta who heads up the M3 Global Research business development teams in the US and EU, “M3’s focus for 2013 has been on the 3 Q’s of Quality, Quantitative, and Qualitative healthcare research.”

About M3 Group
The M3 Group operates in the US, Asia, and Europe with over 2.5 million physician members globally via its physician websites such as http://www.m3.com, http://www.mdlinx.com, research.m3.com, http://www.doctors.net.uk and http://www.medigate.net. M3 Inc. is a publicly traded company on the Tokyo Stock Exchange (jp:2413) with subsidiaries in major markets including USA, UK, Japan, S. Korea, and China. M3 Group provides services to healthcare and the life science industry. In addition to market research, these services include medical education, ethical drug promotion, clinical development, job recruitment, and clinic appointment services. M3 has offices in Tokyo, Washington D.C., Fort Washington, PA, Oxford, London, and Seoul.

M3 Group Sites
mdlinx.com | networksinhealth.com | thesmartestdoc.com | research.m3.com | mdlinx.pdr.net

Read the full story at http://www.prweb.com/releases/2013/12/prweb11396437.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Venous Leg Ulcers (Crural ulcer) Global Clinical Trials Review, H1, 2013
2. Special Offer on Pharma Country Reports Bundle by GlobalData Available at MarketPublishers.com
3. BCC Research Publishes A New Report On Global Markets For Reproductive Technologies
4. BioPharm Insight Releases Quarterly Licensing Information on Global Drug Development
5. AMD Global Telemedicine Announces Integration of Encounter Management Software with Patient Records Management System
6. New report illustrates persistent global burden of anemia among high-risk populations
7. Matakina Launches Volumetric Breast Imaging Tools Built upon Globally Used, Multi-Vendor VolparaDensity Volumetric Breast Density Software
8. BCC Research Publishes A New Report On Global Markets For Waste And Wastewater Treatment
9. Hemodialysis Industry for Global and China 2013 Analysis in New Research Report at ChinaMarketResearchReports.com
10. Medical Tourism Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
11. Global And China X-Ray Machine Industry 2013 Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... , ... Are You Concerned About Mold In Your Home or Workplace? ... Companies in VA, MD and DC, recently completed its application for the new District ... in the district of Columbia is a good thing stated John Taylor, Owner of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, ... of its 60-day free trial program for all of the company’s desktop riser ... a truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... Through an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to ... “Early on I learned that medicine is about more than making diagnoses and prescribing ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. ... months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) ... a significantly better safety and tolerability profile of ropeginterferon alfa-2b ... from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV to ... PharmaEssentia intends to present this data to the FDA ...
(Date:12/4/2016)... 3, 2016 Sickle cell disease (SCD) is ... blood cells that get stuck in veins and block ... failure, and complications leading to death. Each year, approximately ... and most of them lack access to comprehensive care ... long-term therapy for SCD, a pill called hydroxyurea approved ...
Breaking Medicine Technology: